Emergent BioSolutions Inc

EBS

10.920USD

+0.380+3.61%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Emergent BioSolutions Inc's Score

Industry at a Glance

Industry Ranking

72 / 159

Overall Ranking

190 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Emergent BioSolutions Inc Highlights

StrengthsRisks

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Overvalued

The company’s latest PE is 7.68, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 39.86M shares, increasing 0.32% quarter-over-quarter.

Held by HOTCHKIS & WILEY

Star Investor HOTCHKIS & WILEY holds 880.00 shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

13.500

Target Price

+28.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Emergent BioSolutions Inc is 8.31, ranking 76 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 231.10M, representing a year-over-year decrease of 21.34%, while its net profit experienced a year-over-year decrease of 55.40%.

Score

Industry at a Glance

Previous score

8.31

Change

0



Financials

6.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.97

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.63

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Emergent BioSolutions Inc is 5.86, ranking 137 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 7.68, which is 27.29% below the recent high of 9.78 and 150.19% above the recent low of -3.86.

Score

Industry at a Glance

Previous score

5.86

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 72/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Emergent BioSolutions Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 13.50, with a high of 15.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Emergent BioSolutions Inc is 6.82, ranking 103 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 12.83 and the support level at 9.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Emergent BioSolutions Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 83.14%, representing a quarter-over-quarter decrease of 2.05%. The largest institutional shareholder is The Vanguard, holding a total of 3.55M shares, representing 6.77% of shares outstanding, with 14.28% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

3.90M

+1.97%

The Vanguard Group, Inc.

Star Investors

3.54M

-1.21%

State Street Investment Management (US)

2.45M

+40.50%

American Century Investment Management, Inc.

2.38M

+3.94%

Dimensional Fund Advisors, L.P.

2.14M

+15.75%

Palisade Capital Management, LLC

1.43M

+29.67%

Charles Schwab Investment Management, Inc.

1.38M

+25.02%

Geode Capital Management, L.L.C.

1.28M

-0.02%

Acadian Asset Management LLC

1.18M

+20.84%

Connor, Clark & Lunn Investment Management Ltd.

1.13M

+14.76%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Emergent BioSolutions Inc is 4.03, ranking 96 out of 159 in the Pharmaceuticals industry. The company's beta value is 2.37. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Emergent BioSolutions Inc

EBS

7.02 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment